

CORRECTION

Correction: Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany

Florian Schwarz, Habibollah Arefian, Michael Hartmann, Ingo Runnebaum

There is an error in affiliation 5 for author Ingo Runnebaum. The correct affiliation 5 is: Cancer Center Central Germany, Jena, Germany.

Reference

1. Schwarz F, Arefian H, Hartmann M, Runnebaum I (2022) Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. PLoS ONE 17(12): e0278460. <https://doi.org/10.1371/journal.pone.0278460> PMID: 36454738



OPEN ACCESS

Citation: Schwarz F, Arefian H, Hartmann M, Runnebaum I (2024) Correction: Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. PLoS ONE 19(5): e0303776. <https://doi.org/10.1371/journal.pone.0303776>

Published: May 9, 2024

Copyright: © 2024 Schwarz et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.